Welcome to our dedicated page for Scisparc news (Ticker: SPRC), a resource for investors and traders seeking the latest updates and insights on Scisparc stock.
SciSparc Ltd. (Nasdaq: SPRC) generates news across clinical-stage pharmaceuticals, intellectual property, medical devices, and advanced computing initiatives. Through its majority-owned subsidiary NeuroThera Labs Inc., the company reports progress on cannabinoid-based drug candidates, patent grants, and collaborations targeting central nervous system and neuropsychiatric disorders.
Investors following SPRC news can expect updates on drug development programs such as SCI-110, for Tourette syndrome and for the treatment of Alzheimer’s disease and agitation, and SCI-210, for autism spectrum disorder (ASD) and status epilepticus. Company announcements also cover patent activity, including NeuroThera’s opioid–N-acylethanolamine platform for pain management and MEAI-based combination therapies for depression and addiction-related indications.
SciSparc’s news flow extends to corporate transactions and strategic repositioning. Recent disclosures include the transfer of its advanced clinical-stage pharmaceutical portfolio and its stake in SciSparc Nutraceuticals Inc. into NeuroThera Labs Inc., the sale of oncology-focused subsidiary MitoCareX Bio Ltd. to N2OFF, Inc., and a binding term sheet followed by a definitive agreement to acquire a treasury of patents and trademarks for innovative endoscopic systems and medical cameras, including the MUSE system for GERD treatment.
Another recurring theme in SPRC news is technology-driven R&D. The company has announced a quantum computing-enabled 3D protein modeling initiative aimed at improving drug discovery, as well as a non-binding term sheet for NeuroThera to acquire a majority stake in a quantum bio data analysis company. Regulatory and capital markets items, such as Nasdaq compliance notifications, warrant inducement agreements, and SEC Form 6-K filings, also appear in its news stream. For a structured view of these developments, the SciSparc news page aggregates press releases and related coverage in one place.
SciSparc Ltd. (NASDAQ: SPRC), a clinical-stage pharmaceutical company, will present at the Aegis Capital Corp. Virtual Conference on February 24, 2022, at 8:30 a.m. EST. The conference runs from February 23-25, 2022. Interested parties can access the presentation by requesting it from Aegis during the conference dates. The slide deck will also be available on SciSparc's website. The company is focused on cannabinoid pharmaceuticals, with drug development programs targeting disorders such as Tourette syndrome, obstructive sleep apnea, and autism.
SciSparc Ltd. (NASDAQ: SPRC) announced a new leadership team effective January 10, 2022. Oz Adler has been appointed CEO, while Itschak Shrem becomes President and Amitay Weiss is named Chairman of the Board. Adler has been with the company since September 2017, serving as CFO since April 2018. Weiss joined in August 2020, previously working at Bank Poalei Agudat Israel Ltd. Shrem has been Chairman since August 2020 and has extensive experience in financial markets. SciSparc focuses on developing cannabinoid-based pharmaceuticals for conditions like Tourette syndrome and Alzheimer's disease.
SciSparc Ltd. (NASDAQ: SPRC) has announced an agreement with Hannover Medical School and Tel-Aviv Sourasky Medical School to advance its Phase IIb clinical study for SCI-110, a drug aimed at treating Tourette syndrome. The study will be led by renowned experts and is a double-blind, placebo-controlled trial evaluating SCI-110's efficacy and safety for adults aged 18-65. SCI-110 combines dronabinol with palmitoylethanolamide and is developed to enhance THC effectiveness while reducing side effects. The study aims to address the unmet medical need for effective treatments in Tourette syndrome, a condition affecting approximately 1% of the global population.
SciSparc Ltd. (NASDAQ: SPRC) has initiated an examination of psychedelic compounds as potential additions to its intellectual property portfolio. The growing interest in psychedelics could align with the company's focus on disorders of the central nervous system. A report suggests the psychedelic therapy market may reach over $10 billion by 2027, up from $4.75 billion in 2020. Chief Technologies Officer Adi Zuloff-Shani expressed optimism about the compatibility of psychedelic compounds with the company's existing drug development programs, which target conditions such as Tourette syndrome and Alzheimer's disease.
SciSparc Ltd. (NASDAQ: SPRC) announced the recruitment of its first patient for a Phase IIa clinical trial investigating the safety, tolerability, and efficacy of SCI-110 in treating Alzheimer's disease and associated agitation. Conducted at the Israeli Medical Center for Alzheimer's, the trial aims to provide an efficient treatment option amid limited existing therapies. SCI-110 combines synthetic Δ⁹-THC and Palmitoylethanolamide to address behavioral disturbances commonly observed in Alzheimer's patients, with the hope of improving their quality of life.
SciSparc Ltd. (NASDAQ: SPRC) announced a significant milestone with the granting of U.S. Patent No. 11,207,290, covering cannabinoid and N-acylethanolamine combinations for treating central nervous system disorders. This achievement is deemed crucial for the company, as it strengthens their intellectual property portfolio, now comprising four U.S. patents, along with similar patents in Australia and Japan. The patent emphasizes the uniqueness of their methodologies and compounds, reinforcing SciSparc's commitment to developing effective treatments for patients facing currently untreatable conditions.